AbbVie Is Raising Its 2024 Adjusted EPS Guidance From $10.97-$11.17 To $11.13-$11.33, Which Includes An Unfavorable Impact Of $0.08 Per Share Related To Acquired IPR&D And Milestones Expense, Versus Consensus Of $11.12
Portfolio Pulse from Benzinga Newsdesk
AbbVie has increased its 2024 adjusted EPS guidance from the range of $10.97-$11.17 to $11.13-$11.33, despite an unfavorable impact of $0.08 per share due to acquired IPR&D and milestones expense. This new guidance is slightly above the consensus estimate of $11.12.
April 26, 2024 | 11:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie has raised its 2024 adjusted EPS forecast, now exceeding analyst consensus despite additional expenses from acquired IPR&D.
Raising EPS guidance typically signals a company's confidence in its future earnings potential, which can positively influence investor sentiment and potentially lead to a short-term increase in stock price. AbbVie's new guidance surpassing consensus estimates further strengthens this outlook, suggesting a positive impact on ABBV's stock in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100